MedTrace Logo

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-01-04

No results posted yet for this study

Summary

This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).

Conditions

Interventions

DRUG

NCO-48 Fumarate 4 mg

2 x 2mg NCO-48 Fumarate over 28 days of therapy

DRUG

NCO-48 Fumarate 20 mg

2 x 10 mg NCO-48 Fumarate over 28 days of therapy

DRUG

Tenofovir Alafenamide 25 mg

25 mg over 28 days of therapy

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    collaborator INDUSTRY

  • Nucorion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Keith Marschke · Ligand Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2022-09-30
Completion
2022-12-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04629976 on ClinicalTrials.gov